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Abstract
Background The serotonin (5-HT) deficiency hypothesis of
aggression is being seriously challenged by pharmacological
data showing robust anti-aggressive effects of 5-HT1A recep-
tor agonists in dose ranges that concomitantly inhibit 5-HT
neurotransmission. Hence, an adequate interpretation of the
role of 5-HT activity in regulating aggression depends on elu-
cidating the predominant site of action, i.e., raphe presynaptic
autoreceptors versus forebrain postsynaptic heteroreceptors,
of these 5-HT1A receptor agonists.
Objectives The present experiments investigated the anti-
aggressive properties of the selective 5-HT1A receptor ago-
nists F15599 that preferentially target postsynaptic 5-HT1A
heteroreceptors in the frontal cortex and F13714 that more
preferentially activates raphe somatodendritic 5-HT1A
autoreceptors.
Methods Both ‘biased’ agonists were acutely administered
intraperitoneally in aggressive resident male WTG rats
confronting an intruder.
Results Systemic administration of F15599 and F13714
exerted very potent (ID50=0.095 and 0.0059 mg/kg, respec-
tively) anti-aggressive effects. At 4.5-fold higher dose ranges,
the anti-aggressive effects were accompanied by concomitant
motor inactivity and/or reduction of social engagement.
Pretreatment with WAY-100635 counteracted the behavioural
effects of both agonists.
Conclusions Overall, the qualitatively similar but quantita-
tively different anti-aggressive profiles of F15599 and
F13714 largely correspond to their distinct 5-HT1A receptor
binding/activation potencies. Moreover, the marked anti-
aggressive potency of F13714 adds additional support for a
critical role of raphe somatodendritic 5-HT1A autoreceptors,
and hence phasic 5-HT neuron activity, in the initiation/
execution of aggressive actions.
Keywords Aggressive behaviour . Serotonin . 5-HT1A .
Autoreceptors . Heteroreceptors . Dorsal Raphe . F15599 .
F13714
Introduction
Ever since the initial discoveries that serotonin (5-hydroxy-
tryptamine, 5-HT) serves as a neurotransmitter in the brain
(Brodie et al. 1955) and that reduced levels of this indolamine
(and/or its metabolite 5-hydroxyindole acetic acid, 5-HIAA)
were found to be associated with aggressiveness in mice
(Maas 1962; Valzelli and Garattini 1968). this evolutionary
ancient and extremely well-conserved neurotransmitter sys-
tem is generally considered the primary molecular orchestra-
tor of aggressive behavioural traits in virtually every animal
species, including man (see Duke et al. 2013 and de Boer et al.
2015 for review). However, the direction and exact causal
linkage of this association is very complex, and it has proven
notoriously difficult to unravel the precise role of this amine
(and every facet of its synthetic and metabolic pathways, up-
take and storage processes and dynamic receptor signaling
mechanisms) in the predisposition for and execution of ag-
gressive behaviour in both its normal and pathological forms.
For decades, high levels of aggressive behaviour were be-
l i e v ed t o be a s so c i a t e d w i t h l ow b r a i n 5 -HT
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neurotransmission activity (see Manuck et al. 2006; Coccaro
et al. 2015 and Rosell and Siever 2015 for reviews). However,
this seductively simple serotonin deficiency hypothesis of in-
creased aggression is being challenged (de Boer and Koolhaas
2005; Carrillo et al. 2009; Duke et al. 2013; Takahashi and
Miczek 2014; Takahashi et al. 2015) by a substantial database
showing robust anti- or pro-aggressive effects of pharmaco-
logical agents in dose ranges that concomitantly inhibit or
enhance, respectively, phasic 5-HT neuron firing and/or ter-
minal release of 5-HT. In particular, agonists of 5-HT1A sub-
type receptors are among the most potent drugs to suppress the
initiation and execution of offensive aggressive behavioural
displays in various vertebrate species ranging from fish, ro-
dents, guinea pigs, canines to primates, including man (see de
Boer and Koolhaas 2005 and Takahashi et al. 2012 for review
and relevant Citations). This anti-aggressive effect only cor-
roborates the 5-HT deficiency hypothesis of aggression under
the assumption that these agonists would mainly act on the
postsynaptic 5-HT1A heteroreceptor population, i.e. mimick-
ing higher 5-HT activity. However, the 5-HT1A receptors are
not only found post-synaptically as inhibitory heteroreceptor
on various non-5-HT neurons in critical brain regions of the
social behavioural (aggression) network, including the hypo-
thalamus, amygdala, periaqueductal gray, septum and frontal
cortex, but also as major inhibitory autoreceptor on the soma
and dendrites of dorsal raphe 5-HT neurons (i.e. 5-HT1A
autoreceptor) that project to these forebrain areas. Hence, at
the presynaptic somatodendritic level, these systemically ap-
plied agonists very effectively reduce 5-HT (re)activity,
whereas at the level of the postsynaptic 5-HT1A
heteroreceptors they mimic the effects of an enhanced 5-HT
signaling. This indicates that the autoregulatory negative feed-
back mechanism may obscure a simple linear relationship
between aggression and 5-HT neurotransmission, and that a
proper interpretation of the role of serotonin in regulating ag-
gression depends on elucidating the predominant site of action
of these 5-HT receptor agonists.
Furthermore, current drugs acting as full 5-HT1A agonists
are generally suboptimal in their specific anti-aggressive pro-
file of activity because they indiscriminately activate 5-HT1A
receptors subpopulations in brain regions that mediate a host
of other behavioural (locomotion, sleep, body care, appetite,
sex), neuroendocrine (HPA-activation, prolactin release) and
autonomic physiological responses (hypothermia, bradycardia
and hypotension). Not surprisingly, therefore, the anti-
aggressive effects of most full 5-HT1A receptor agonists are
usually accompanied with, or even may be primarily caused
by, a concomitant reduction of initiative motor activity, social
engagement and/or physiological thermogenic and cardiovas-
cular functioning, e.g. rendering them behaviourally rather
non-specific (de Boer et al. 2000).
However, some 5-HT1A agonists can more selectively re-
duce aggressive behaviours without affecting other non-
aggressive behaviours. For example, the highly selective but
low efficacy 5-HT1A receptor agonist S-15535, that generally
acts in-vivo as a preferential agonist on 5-HT1A
autoreceptors but as a weak partial (ant)agonist on post-
synaptic 5-HT1A receptor sites (Carli et al. 1999; Millan
et al. 1994). exerted a rather consistent and behavioural-
selective reduction in aggressive behaviour over a wide
dose range (Millan et al. 1997; de Boer et al. 2000).
These data strongly indicate that the acute aggression-
reducing effects of 5-HT1A agonists are predominantly
due to their action on the inhibitory autoreceptors, pre-
sumably attenuating a phasic social conflict (intruder)-
activated 5-HT neurotransmission (de Boer and
Koolhaas 2005; and discussion for further support of
this view). Hence, it would be desirable to select com-
pounds that preferentially interact with 5-HT1A
autoreceptor subpopulations mediating anti-aggressive
properties, while minimizing interactions with 5-HT1A
heteroreceptor subpopulations that are predominantly in-
volved in various other behavioural and/or physiological
functions.
Recently, several exceptionally selective and high-affinity
5-HT1A receptor agonists have been developed that are shown
to very efficiently activate different subpopulations of 5-HT1A
receptors in the brain, presumably depending upon their cou-
pling to G-protein subunits and/or intracellular second-
messenger pathways, i.e. the so-called ‘biased’ or ‘function-
ally selective’ agonists (Newman-Tancredi 2011; Garcia-
Garcia et al. 2014). For example, F15599 is an extremely
selective and with high binding affinity (Ki = 3.4 nM) 5-
HT1A receptor agonist that exhibits preferential affinity for
postsynaptic 5-HT1A heteroreceptors in (prefrontal)cortical re-
gions compared to presynaptic 5-HT1A autoreceptors. On the
other hand, its chemical congener F13714 has a similar high
receptor selectivity and even 30-fold higher (Ki=0.1 nM) re-
ceptor binding affinity than F15599 but seems to more pref-
erentially activate the 5-HT1A autoreceptor pool in the raphe
nuclei (Newman-Tancredi 2011; Garcia-Garcia et al. 2014).
Moreover, within cortical tissues, F15599 may even distin-
guish 5-HT1A receptors expressed on glutaminergic pyramidal
cells from those expressed on theGABAergic interneurons, an
assertion based on the U-shaped dose–response curves seen
after local microinjection of the drug into the medial prefrontal
cortex in the forced swim test (Newman-Tancredi 2011) and
resident-intruder aggression paradigm (Stein et al. 2013).
Relevant for the current objectives is particularly the latter
study demonstrating that local microinjection of low doses
(0.03 and 0.2 μg) F15599 into the medial prefrontal cortex
region of male mice were effective in reducing aggression but
no effects were seen with higher doses (0.3 and 1.0 μg). This
biphasic effect may be due to the fact that F15599 preferential
activates 5-HT1A receptors onGABAergic interneurons, caus-
ing a decrease of the inhibition of pyramidal neurons and
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thereby increasing activation of these principal medial pre-
frontal cortex projection neurons critically involved in the
control of aggressive displays (Takahashi et al. 2015).
Regrettably, Stein and coworkers did not test F15599 after
systemic administration or after local microinjection into the
dorsal raphe nucleus, nor did they compare the F15599 effects
with the divergently biased 5-HT1A agonist F13714.
Therefore, the objectives of this study were to assess and
compare the possible anti-aggressive potencies of F15599
and F13714 in rats, both administered systemically and after
microinjection into the dorsal raphe nucleus, with the main
aim to further elucidate the relative contribution of
somatodendr i t ic autoreceptors and postsynapt ic
heteroreceptors in the potent anti-aggressive properties of 5-
HT1A receptor agonists. Special attention was paid to behav-
ioural selectivity as well as receptor specificity of the antici-
pated anti-aggressive effects of these biased 5-HT1A agonists
by employing a detailed quantitative ethological analysis
methodology and testing whether the biased agonists’ behav-
ioural effects can be abrogated by the 5-HT1A receptor antag-
onist WAY-100635. Finally, the behavioural profiles of
F15599 and F13714 were compared with several previously




Male wild-type Groningen (WTG) rats (Rattus norvegicus;
or ig inal ly wild- t rapped animals and bred under
conventionalized conditions for over 50 generations in our
own facility) 4–5 months of age and weighing 379–475 g
(average weight=439±5.0 g) were used as experimental sub-
jects. This outbred strain is very suitable for social and ago-
nistic behaviour studies because of their rich natural repertoire
of social affiliative-aggressive behaviours that differ widely in
intensity among individuals, ranging from no aggression at all
to very high levels of aggressive behaviour (de Boer et al.
2003). Animals were housed in same-sex groups of 5–6 from
weaning (23 days after birth) until the start (at age 145 days) of
the experiments in clear type IV makrolon cages
(60×60×20 cm). The cages were placed in a temperature-
controlled room (21±2 °C) with a fixed 12-h light/dark pho-
toperiod (lights off at 10:00 h). All behavioural tests were
performed in the dark phase (active period of rodents) be-
tween 11:00 and 13:00 h. The animals were allowed continu-
ous free access to water and food. All procedures were con-
ducted in conformity with the ethical rules of the Committee
on Care and Use of Laboratory Animals (DEC) of Groningen
University and European regulations (guideline 86/609/EEC).
Experimental procedures
A resident-intruder agonistic paradigm was employed to
induce offensive behaviour (see Koolhaas et al. 2013 for
detailed procedure and video clips). Briefly, in this para-
digm, male rats are housed individually in large observa-
tion cages (80 × 55 × 50 cm) with an oviduct-ligated (i.e.
sterilized but hormonally intact) female to avoid social
isolation and allow sexual behaviour, thereby facilitating
territorial behaviour. After 1 week, the baseline level of
offensive aggressive behaviour was tested on 3 consecu-
tive days during maximally a 10-min confrontation with
an unfamiliar male conspecific (WTG rats). The female
partner of the experimental rat was removed from the
home observation cage approximately 60 min prior to
the start of this social provocation test. Naïve male
WTG rats, socially housed in groups of 3 in transparent
makrolon type IV cages, were used as conspecific intruder
animals (average weight 372 ± 9.5 g and 3.5–4 months
old). During the first 3 tests, the intruder was removed
immediately after the first full attack from the resident
and the a t tack la tency t ime (ALT) was noted .
Experimental groups were balanced on the basis of the
ALT and the level of offensive behaviour performed dur-
ing the fourth baseline test (day 4), during which the full
range of behaviours was recorded and analysed (see be-
low). Only animals that attacked (i.e. ALT <600 s) were
included in the experimental groups. Non-attacking indi-
viduals (11 out of 144) were excluded from this study. On
the next day (day 5), vehicle (sterile Ultra Pure water, n=19
and n = 20) or either F15599 (0.0625, 0.125, 0.25, 0.5
and 1.0 mg/kg, IP, experiment 1, n=45) or F13714 (0.003,
0.006, 0.012, 0.025, 0.062, 0.125, 0.250, IP, experiment 2,
n = 50) was administered 30 min before the 10 min
confrontation with a drug-free unfamiliar intruder conspecific
and their behaviour was recorded again. In addition,
in experiment 3, animals were tested 30 min after treatment
with either vehicle/vehicle (UP), vehicle/F15599 (0.1 mg/kg)
or F13714, WAY-100635 (0.3 mg/kg)/vehicle or
WAY100635 (0.3 mg/kg)/ F15599 (0.1 mg/kg) or
F13714. Each treatment group consisted of 6–8 subjects
(n=41 animals total).
During the resident-intruder agonistic confrontations on the
non-drug test days 4 and on the drug test days 5, the full range
of behaviours of the experimental resident was video-recorded
and manually scored later on a custom-made data acquisition
system (E-line) by an experimenter blind to treatment condi-
tions. An extensive description of the different behavioural
elements displayed during agonistic interactions has been re-
ported previously (Koolhaas et al. 2013; de Boer et al. 2003).
The frequencies and durations of the different behavioural
elements were determined and expressed as a percentage of
the total duration of the confrontation.
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Drugs
F15599 and F13714 compounds were provided by Pierre
Fabre Pharmaceuticals, France (Lot # SBR1401003 and #
JLM3001201). WAY-100635 was obtained from Sigma-
RBI. All drugs were freshly (on the day of the experiment)
dissolved in, and/or diluted with, vehicle solution (sterile and
pyrogen-free UltraPure water (UP)) approximately 1.5 h be-
fore the start of the drug-testing experiments. The systemic
injections are given intraperitoneally (IP) in a volume of
1 ml/kg body weight.
Data analysis
Behavioural data were expressed as mean± standard error
(SEM). In the dose–response studies, the drug effects on each
behavioural category were also computed as percentage of the
respective vehicle-treated control values to enable compari-
sons between the various drugs. Regression analysis was used
to calculate the dose that would elicit 50 % reduction in ag-
gression (ED50 values). For most of the behavioural variables,
a Shapiro-Wilkinson test for normality of the data indicated
that the underlying population did deviate from a normal dis-
tribution. Hence, data were square-root transformed to nor-
malize before parametric tests were performed. The dose-
effect curves for each behavioural category of the offensive
aggression test were analysed by a one-way ANOVA, with
drug dose as between-subject factor. Further analyses were
made by Dunnett’s test (comparison to the vehicle group) to
determine the source of detected significance in the
ANOVA’s. The criterion of significance was set at P<0.05.
All statistical analyses were performed using SPSS v.22
program.
Results
Offensive aggression test: general aspects
in the undrugged state
Social confrontation initiated by the intrusion of an unfamiliar
male rat into the home cage of the territorial experimental
male counterpart resulted in the typical offensive aggressive
and social behavioural repertoire displayed by the WTG res-
ident rats: The resident male becomes aroused and quickly
moves towards (approach) the intruder followed by social
investigating, ano-genital sniffing and sometimes interspersed
with bouts of grooming (particularly face-washing).
Meanwhile, the intruder either actively explores the cage with
rearing, sniffing and ambulatory movements, explores the res-
ident or stays more passive/inactive by sitting still displaying
only some scanning movements. Depending on the innate
aggressiveness of the individual, the residents show
piloerection and teeth-chattering and move towards the intrud-
er while performing lateral/sideways threatening postures. In
reaction to this, the intruder displays keep off movements and/
or assumes an upright posture. In the latter case, the resident
also adopts this posture maintaining piloerection and/or teeth
chattering. These threatening displays are often followed by a
clinch attack during which biting occurs towards the back,
flank and neck regions of the intruder. These attacks usually
lead to moving away (fleeing) of the intruder, which is then
quickly followed (chasing) by the resident. Sooner or later, the
intruder stops moving away and takes a submissive supine
posture (signaling defeat) when approached and/or kept down
by the resident. The resident male usually stops physically
attacking when the intruder remains passive/supine. These
fights generally occur in a bursting temporal pattern and intri-
cately sequenced bouts of threatening/clinching/chasing are
separated by periods of relative inactivity but alert scanning/
observation. During these gaps, the resident engages in non-
social behavioural acts such as walking, rearing, grooming or
sitting still and scanning.
The latency time to the first attack in the undrugged resi-
dents (n=175) on day 4 ranged from 12 to 600 s with a mean
of 126±28 s. In total, 14 of the 175 rats (8%) did not initiate a
clear attack and hence scored an ALTof 600 s (non-aggressive
individuals). These animals were not further included in drug
testing. During the 10-min test period, after the first clinch/
attack-bite, undrugged resident rats spent 58±4.3 % of the
time on offensive aggressive behaviours and 15.5±3.6 % on
social explorative behaviours, thereby spending 73.5±2.2 %
on total social interaction. In the remaining part of the 10 min
observation period, undrugged animals showed 16.5±1.5 %
non-social exploration, 6.7±1.4 % inactivity and 3.2±0.7 %
grooming. The frequency of clinch attack bites in undrugged
animals during the 10-min agonistic observation period
amounted 18.3±1.7.
Dose–response effects of F15599
A similar behavioural pattern as in undrugged rats was ob-
served on day 5 in the groups of rats injected with vehicle
(UP). In contrast, treatment of the animals with 5 different
doses of F15599 resulted in a significant and dose-
dependent (MED=0.125 mg/kg) delay in the latency to attack,
and a potent reduction (ID50 = 0.095 mg/kg; Fig. 4) in the
amount of aggressive behaviour directed towards the intruder
rat (Fig. 1). This reduction in aggressive behaviour was, at 4.5-
fold higher dose ranges, accompanied by a significant increase
in behavioural inactivity scores (see Fig. 1) and only a slight
(dose 0.125 mg/kg) compensatory increase in social explora-
tion or non-social explorative behaviours (dose 0.125 and
0.25 mg/kg). Hence, a significant dose-dependent reduction
in total social interaction was observed. Starting from the
0.25 mg/kg dose, F15599 induced clear signs of the so-called
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serotonin syndrome characterized by flat body posture, head-
waving, lower lip retraction and hindlimb abduction, leading to
increased behavioural inactivity scores and social disengage-
ment (see Fig. 1). Basically, F15599-treated animals seemed
to not take initiative for active behavioural exploration and/or
actions anymore. Only upon physical provocation by the in-
truder animal, drug-treated residents started to display some
active social explorative behaviours and in certain cases mild
aggressive acts and postures.
Dose–response effects of F13714
Treatment of the animals with 7 different doses of F13714
resulted in a significant dose-dependent delay (i.e.
MED=6 μg/kg) in the latency to attack and a pronounced
suppression (i.e. ID50=0.0059 mg/kg; Fig. 4) in the amount
(number and duration) of aggressive displays towards the con-
specific intruder rats (Fig. 2). At slightly (4.5-fold) higher
dosages, this anti-aggressive effect is accompanied by a potent
increase (i.e. ED50=0.027) in behavioural inactivity (seroto-
nin syndrome-like behavioural displays like flattened body
posture, lower lip retraction and repetitive motor routines like
head-waving and fore-paw treading) and unchanged social
and non-social explorative behaviours; hence, total social in-
teraction scores were concurrently significantly attenuated.
Effective dose of F15599 and F13714 in combination
with WAY-100635
Pretreatment with the selective 5-HT1A receptor antagonist
WAY-100635 (0.1 mg/kg) virtually completely prevented the
anti-aggressive effects of the 0.1 mg/kg dose of F15599 and
the 0.01 mg/kg dose of F13714 (see Fig. 3). While the behav-
ioural performance of only WAY-100635-treated (0.1 mg/kg)
animals was indistinguishable from both the vehicle-treated
animals and their own undrugged behavioural profiles, treat-
ment of animals with only F15599 (0.1 mg/kg) or F13714
(0.01 mg/kg) resulted in a significant delay of the latency to
attack and a potent reduction in the amount and intensity of
aggressive behaviours directed towards the intruder rat.
Discussion
The present findings demonstrate that: (1) systemic adminis-
tration of both F15599 and F13714 exerted very potent dose-
dependent, but with considerable different potencies
(ED50 = 0.095 and 0.0059 mg/kg i.p., respectively), anti-
aggressive effects. (2) At slightly (4.5-fold) higher dosages,
these anti-aggressive actions were accompanied by concurrent
behavioural impairments, indicating only a modest separation
from motor inactivity and reduction of social engagement. (3)
The prototypical selective 5-HT1A receptor antagonist WAY-
100635 completely counteracted the behavioural effects of
both agonists, demonstrating 5-HT1A receptor mediation.
Effects of 5-HT1A biased agonists on aggressive behaviour
The present results add to the large database demonstrating
that 5-HT1A receptor agonists very efficaciously attenuate
offensive-aggressive responses, even at low dose ranges that
do not appear to cause motor impairments (de Boer and
Koolhaas 2005). Furthermore, the qualitatively similar but











































































 0.0625 mg/kg (n=8)
 0.125 mg/kg (n=8)
 0.25 mg/kg (n=13)
 0.5 mg/kg (n=8)
 1.0 mg/kg (n=8)
Fig. 1 Effect of acute systemic (IP) F15599 on the attack latency time
(ALT; insert) and different behavioural categories of resident wild-type
Groningen rats in the offensive aggressive resident-intruder test. One-way
ANOVA revealed significant effects of drug-dose for ALT
[F(5,58) = 17.586; p < 0.0001], offensive behaviour [F(5,58) = 20.579;
p < 0.0001], total social interaction [F(5,58) = 13.626; p < 0.0001],
non-social exploration [F(5,58) = 3.381; p < 0.01] and inactivity
[F(5,58) = 7.664; p < 0.0001]. Asterisk indicates that values are
significantly (p< 0.05; Dunnett’s test) different from the vehicle value.
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F13714 obtained in this study largely correspond to their pre-
viously reported distinct 5-HT1A receptor binding and signal-
ing potencies and partly support the ‘biased agonist’ profile of
action reported for these compounds. Both F15599 and
F13714 are extremely selective 5-HT1A receptor full agonists
with >1000-fold selectivity over other targets (Maurel et al.
2007) and with strikingly high in vitro binding affinities
(Ki=3.4 and 0.1 nM, respectively) (Newman-Tancredi et al.
2009). However, the 30-fold difference in binding affinity
between F13714 and F15599 does not equally translate itself
in in vitro receptor signaling activity or in various in vivo
neurochemical, behavioural and physiological potencies.
More specifically, in tests of signal transduction, F15599 ac-
tivated Gαi-coupled receptors (EC50=110 nM) more potently
and efficaciously than Gαo-coupled receptors (EC50 = 850
nM) while F13714 demonstrated a similar potency (although
still roughly 150-fold and 1000-fold higher than F15599) for
both Gαi (EC50=0.7 nM) and Gαo (EC50=0.8 nM) protein-
coupled receptor activation (Newman-Tancredi et al. 2009).
Subsequently, a large series of different in vivo studies have
demonstrated that the in vitro signaling bias of F15599 to
activate 5-HT1A receptors translates to a preferential activation
of cortical postsynaptic 5-HT1A heteroreceptors with less in-
fluence on presynaptic 5-HT1A autoreceptors. By contrast,
F13714 exhibits an opposite preference, with more pro-
nounced activation of 5-HT1A autoreceptors and less potent
activity at cortical heteroreceptors (Newman-Tancredi 2011;














































































 0.003 mg/kg (n=8)
 0.006 mg/kg (n=8)
 0.012 mg/kg (n=8)
 0.025 mg/kg (n=8)
 0.062 mg/kg (n=6)
 0.125 mg/kg (n=6)
 0.250 mg/kg (n=6)
Fig. 2 Effect of acute systemic (IP) F13714 on the attack latency time
(ALT; insert) and different behavioural categories of resident wild-type
Groningen rats in the offensive aggressive resident-intruder test. One-way
ANOVA revealed significant effects of drug-dose for ALT [F(7,69) =
28.31; p < 0.0001], offensive behaviour [F(7,69) = 29.11; p < 0.0001],
total social interaction [F(7,69) = 2.75; p<0.002], non-social exploration
[F(7,69) = 2.33; p < 0.01 and inactivity [F(7,69) = 17.86; p < 0.0001].
Asterisk indicates that values are significantly (p < 0.05; Dunnett’s test)
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 Veh/F13714 (0.01 mg/kg)































Fig. 3 Antagonism of the anti-
aggressive effects of F15599 and
F13714 by pretreatment with
WAY-100,635. One-way
ANOVA revealed significant
effects of treatment for ALT
[F(5,34) = 6.32; p< 0.0001],
offensive behaviour
[F(5,34) = 4.36; p< 0.005] and
total social interaction
[F(5,34) = 2.70; p< 0.05]. Each
treatment group consisted of 6–8
subjects. Asterisk indicates that
values are significantly (p< 0.05;
Dunnett’s test) different from the
vehicle/vehicle values
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action of F15599 will accentuate those behavioural and phys-
iological effects that are assumed to be mediated by activation
of postsynaptic heteroreceptors rather than presynaptic
autoreceptors as summarized recently (Newman-Tancredi
2011). Thus, if activation of postsynaptic 5-HT1A
heteroreceptor populations were predominantly responsible
for suppression of offensive aggression, F15599 should have
exerted an anti-aggressive potency close to or even higher
than F13714. However, our data clearly demonstrate a 16-
fold lower anti-aggressive potency of F15599 compared to
F13714 and this potency difference is roughly similar to or
even higher than that observed for other behavioural and neu-
rochemical effects (prepulse-inhibition deficit, 5CSRTTatten-
tional deficit, inhibition 5-HT release) that are believed to be
predominantly mediated by activation of raphe 5-HT1A
autoreceptors. Moreover, the anti-aggressive dosages of both
F15599 and F13714 correspond to dose ranges that exert de-
creases in extracellular 5-HT in the hippocampus and prefron-
tal cortex with microdialysis studies, responses that
undisputably are under rigorous 5-HT1A autoreceptor control
(Llado-Pelfort et al. 2010; Iderberg et al. 2015).
Interestingly, since it was shown that F13714 very rapidly
(within just 3 days of treatment with 2.5 mg/kg/day)
desensitized somatodendritic 5-HT1A autoreceptors upon
(sub)chronic administration Assié et al. (2006). it would be
very relevant in future experiments to investigate the effec-
tiveness of repeated and/or more sustained F13714 adminis-
tration to suppress trait-like aggressiveness, particularly in
subjects that demonstrate violent-like and excessive forms of
aggression. Actually, one of the biggest problems of almost all
behavioural pharmacological studies performed today is the
predominantly acute treatment regimens, influencing the neu-
rochemical target only for a very short period of time. If com-
ponents of the serotonergic system are functionally and/or
structurally adapted to (or basically underlying) the aggressive
phenotype of an animal or human, it probably will take long-
term treatment to reverse the activity to normal. On the other
hand, (sub)chronic drug-induced alterations of the functional
capacity of receptors, such as desensitization of 5-HT1A
autoreceptors, is a well-known phenomenon and may also
lead to rapid or gradual tolerance to a drug’s proposed thera-
peutic efficiency.
Separation of anti-aggressive and inactivity-inducing
doses
Similar to almost all full 5-HT1A receptor agonists tested so far
in a wide variety of animals species and aggression para-
digms, the present anti-aggressive actions of F15599 and
F13714 at higher dosages are largely accompanied with
slowed motor activity and reduced social engagement.
Comparing the anti-aggressive ED50 values with the ED50
values of increasing behavioural inactivity scores (Fig. 4), it
appears that all full agonists have a 4.5-fold separation be-
tween the anti-aggressive and pro-inactivity potencies. In gen-
eral, it has been proven very difficult to clearly dissociate the
anti-aggressive effects of full 5-HT1A receptor agonists from
their various other behavioural (locomotion, sleep, body-care,
appetite, sex), neuroendocrine (HPA-activation, prolactin
release) and autonomic physiological responses (hypother-
mia, bradycardia and hypotension). One reason for this very
narrow ‘therapeutic’ window is likely due to the combination
of the fact that most full agonists do not seem to sufficiently
discriminate between different (i.e. pre-versus post- synaptic)
subpopulations of 5-HT1A receptors and their intrinsic high-
efficacy to activate them. Hence, even the present highly effi-
cacious but biased 5-HT1A receptor agonists, F13714 and
F15599, do not exert as favourable a serenic-like profile of
action as has been observed for some other selective but low-
efficacy 5-HT1A agonists like S-15535 (de Boer et al. 2000).
the mixed 5-HT1A/B partial agonists like eltoprazine (Olivier
2004; de Boer et al. 2000) and more selective 5-HT1B agonists






























































 F13714 (0.0059; 0.027))
 8-OHDPAT (0.068; 0.21)
 F15599 (0.095; 0.43))
 Buspirone (0.69; 0.98)
 Ipsapirone (0.81; 3.54)
 Alnespirone (0.75; NA)
 S-15535 (0.75; NA)
 Eltoprazine (0.27; 0.46)
Fig. 4 Comparative potency of different 5-HT1A receptor agonists to
inhibit offensive aggression (top panel) and to enhance motor inactivity
(bottom panel) in the rat resident-intruder offensive aggression test. In the
legend, the numbers in between the parentheses indicate the ED50 values
of the drug’s anti-aggressive and inactivity-enhancing potency,
respectively
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like CP-94,253 (Miczek et al. 2004; de Boer and Koolhaas
2005). It should be noted, however, that the induction of typ-
ical serotonergic syndrome-like behaviours such as forepaw
treading and flat body posture by F13714 and F15599 in
WTG rats occurred at lower doses than those reported previ-
ously for these drugs in other rat strains (e.g. Sprague–
Dawley, Assié et al. 2010). The dose separation between
anti-aggressive and syndrome/inactivity-inducing effects
could therefore vary in different rat strains. In addition, induc-
tion of serotonergic behaviours by 5-HT1A agonists rapidly
desensitizes upon repeated administration (e.g. Iderberg
et al. 2015), emphasizing, once again, the importance of in-
vestigating the effects of such drugs under chronic adminis-
tration regimens, as mentioned above.
Importance of 5-HT1A auto- and heteroreceptors
in aggressive behaviour
Together with our previous work testing the anti-aggressive
effects of several different 5-HT1A receptor agonists (de Boer
et al. 2000; De Boer and Koolhaas 2005). the marked anti-
aggressive potency of F13714 in this study provides addition-
al evidence that the anti-aggressive effects of systemic 5-HT1A
receptor agonists are largely expressed via their efficacious
action on the inhibitory autoreceptors located on the soma
and dendrites of raphe 5-HT neurons, presumably by attenu-
ating intruder-activated 5-HT neuronal activity. Indeed, sub-
stantial evidence suggests that the actual display of offensive
aggressive behaviour, or at least the intent thereof, is associ-
ated with (short-lasting) increased 5-HT neuronal activity. For
example, robust increases of molecular neuronal activation
markers in 5-HT-positive raphe neurons were found after the
display of aggressive behaviour in rats and mice (Van der Vegt
et al. 2003; Veening et al. 2005; Haller et al. 2005, 2006).
Also, fMRI imaging in aggressively motivated rats has re-
vealed a robust but shortlasting increase of the BOLD signal
in the dorsal raphe area (Ferris et al. 2008). In addition, several
in vivo microdialysis experiments in mice have clearly dem-
onstrated that 5-HT release increased within the dorsal raphe
nucleus, hippocampus and/or the medial prefrontal cortex
when animals were aggressively aroused by social instigation
and during escalated aggression after social instigation
(Cadogan et al. 1994; Takahashi et al. 2011, 2015).
Moreover, by employing wireless voltammetry techniques,
phasic serotonin increases within the ventral striatum were
found in resident rats confronting intruders (Nakazato 2013).
Finally, direct pharmacological activation of 5-HT1A
autoreceptors in the dorsal raphe nucleus employing local mi-
croinjection of 5-HT1A receptor agonists that potently sup-
press 5-HT neuron activity, consistently reduced aggressive
behaviour in rats and mice, although in most cases also with
a concurrent reduction inmotor activity and social interactions
(Mos et al. 1992; de Almeida and Lucion 1997; Van der Vegt
et al. 2003; Calcagnoli et al. 2015). Preliminary findings
employing direct intra- dorsal raphe microinjections of both
F15599 and F13714 also revealed potent anti-aggressive ef-
fects (data not shown). This persuasive database support the
view of rapid transient increases in 5-HT neuronal activity
when an individual prepares or initiates imminent aggressive
acts, and this view seems consistent with the classic theory on
global brain 5-HT function that activation of the 5-HT system
is most strongly related to general arousal and locomotor out-
put (Jacobs et al. 2002; Beekman et al. 2005). However, the
above view appears to be at odds with two other reports in the
literature. One single and rather dated in vivo electrophysio-
logical study in male tree shrews showed that serotonin neu-
ron firing rates were reduced in dominant males immediately
before an agonistic encounter (Walletschek and Raab 1982).
Another very interesting recent pharmacogenetic study in
male mice demonstrated that rapid suppression of 5-HT neu-
ron firing by 5-HT1A receptor agonist 8-OHDPAT treatment
of genetically engineered mice expressing the 5-HT1A recep-
tor exclusively on 5-HT neurons led to a mild increase in
aggressive responding (Audero et al. 2013). This particular
data set cannot yet easily be reconciled with the above-
outlined substantial database showing robust anti-aggressive
effects of 5-HT1A agonists in dose ranges that concomitantly
inhibit phasic 5-HT neuron firing and terminal release of 5-
HT. However, the recent rapidly advancing tools that enable
measuring and manipulating neural activity of molecularly
defined neuronal subtypes promise to elucidate the proposed
causal relationship between dorsal raphe serotonin neuron ac-
tivity and the various aspects of aggressive behaviour (Miczek
et al. 2015).
Furthermore, it should be noted that aggression has to be
conceptualized into two components, state-like aggression
and trait-like aggressiveness. Whereas the latter refers to an
individual’s personality and predisposition for acting aggres-
sively, state-like aggression refers to the actual display of ag-
gressive behaviours. While the normal initiation and display
of offensive aggressive behaviour seems positively related to
5-HT impulse flow (i.e. state-like change), an inverse relation-
ship probably exists between tonic 5-HTactivity (i.e. trait-like
phenomenon) and the likelihood to engage in impulsive and
violent outbursts. Indeed, enduring lowered levels of 5-HTare
generally reported to correlate with excessive levels and/or
uncontrolled forms of aggressive conduct (see de Boer et al.
2015 for a further detailed review of this aspect). Based on the
observations that high trait-like aggressive rats and mice are
characterized by enhanced somatodendritic 5-HT1A
autoreceptor activity, a causal role was suggested for these
autoreceptors in tonically suppressing brain 5-HT neurotrans-
mission activity and the predisposition for high and excessive
aggressive responding (de Boer et al., 2001; De Boer et al.
2009, 2015; Van der Vegt et al. 2001; Caramaschi et al. 2008).
The recent molecular genetic studies by Gross and colleagues
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have indeed convincingly confirmed this causality by show-
ing that adult transgenic mice with conditional overexpression
of somatodendritic autoreceptors chronically suppressed 5-
HT neural firing and phenotypically exhibited heightened ag-
gressiveness (Audero et al. 2013).
Although the anti-aggressive effects of systemic 5-HT1A
receptor agonists are likely to be mostly mediated via the
raphe 5-HT1A autoreceptor activation, the activation of multi-
ple populations of postsynaptic 5-HT1A heteroreceptors by
means of local microinjection into several key nodes of the
aggression neural circuitry, including orbital and medial pre-
frontal cortex (Centenaro et al. 2008; Stein et al. 2013). hypo-
thalamus (Cologer-Clifford et al. 1997), periaqueductal gray
(Shaikh et al. 1997) and medial amygdala (de Almeida and
Lucion 1997) have been shown to be effective in suppressing
several forms of aggressive behaviour as well. However, acti-
vation of 5-HT1A receptors in prefrontal cortical regions and
septum (de Almeida and Lucion 1997) can also promote an
increase in aggressive behaviour, suggesting the existence of
functionally opposite post-synaptic 5-HT1A heteroreceptor
populations. Nevertheless, it is conceivable that after systemic
administration of 5-HT1A receptor agonists, activation of these
postsynaptic heteroreceptors may contribute to the anti-
aggressive effects as well. Actually, the postsynaptic 5-HT1A
heteroreceptor-mediated anti-aggressive effects may be accen-
tuated in the situation when local 5-HT release is being atten-
uated due to the concomitant activation of the somatodendritic
5-HT1A autoreceptors, and thereby also decreasing the activa-
tion of all other non-5-HT1A receptors in the brain. In addition
to local microinjection studies of 5-HT1A receptor agonists in
various brain regions to reveal the relative contributions of
each population of 5-HT1A receptor to the antiaggressive ef-
fects, another potential useful experimental design could be to
systemically administer 5-HT1A receptor agonists and then
locally block 5-HT1A receptors by microinfusion of the 5-
HT1A receptor antagonist WAY-100635.
Translational perspectives and Conclusions
Considering our emerging preclinical understanding of the
psychopharmacology and neurobiology of aggression com-
bined with the urgent clinical need to better and more effica-
ciously manage the rapidly increasing population of highly
agitated and aggressive individuals with psychiatric problems
and/or neurodegenerative disorders, it is quite disappointing to
see relatively little clinical research effort and trials to bring
se lec t ive 5-HT1A/B receptor agonis ts in to dai ly
pharmacotherapeutic practice. Unfortunately, the current treat-
ment of exaggerated aggression usually involves the prescrip-
tion of combinations of drugs which by themselves are nor-
mally used to treat epilepsy (anticonvulsants), schizophrenia
(anti-psychotics), anxiety (benzodiazepines) or depression
(SSRI antidepressants) (Comai et al. 2012). Given the
generally non-selective psychopharmacological profiles of
these drug classes, it is not surprising that only poor therapeu-
tic efficacy and/or a host of unwanted and adverse side effects
have been reported for these drugs (Goedhard et al. 2006;
Comai et al. 2012). Nevertheless, there are several reports that
treating excessively aggressive and agitated patients afflicted
with several neuropsychiatric disorders with rather non-
selective 5-HT1A receptor agonists (buspirone, eltoprazine)
can be effective in reducing several measures of aggressive
responding (Stanislav et al. 1994; Pfeffer et al. 1997; Ratey
et al. 1991; Ricketts et al. 1994; Mak et al. 1995). Similarly,
chronic treatment regimens with several different SSRIs that
are all well known to indirectly lead to desensitization of 5-
HT1A autoreceptors were found to be variously effective in
curbing aggressiveness and agitation in psychiatric and
Alzheimer patients (Coccaro et al. 1997; McDougle et al.
1996; Vartiainen et al. 1995; Weintraub et al. 2015;
Underwood and Fox 2014). Currently, there are no clinical
studies available yet using selective and high-efficacy 5-
HT1A agonists as potential anti-aggressive agents. We there-
fore propose that (sub)chronic treatment with selective and
highly efficacious ‘autoreceptor biased’ 5-HT1A agonists like
F13714 may have clinical potency to normalize (trait-like)
excessive aggressive and violent conduct in patients with dif-
ferent psychiatric disorders or neurodegenerative diseases like
Alzheimer’s.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Assié MB, Lomenech H, Ravailhe V, Faucillon V, Newman-Tancredi A
(2006) Rapid desensitization of somatodendritic 5-HT1A receptors
by chronic administration of the high-efficacy 5-HT1A agonist,
F13714: a microdialysis study in the rat. Br J Pharmacol 149:170–
178
Assié MB, Bardin L, Auclair AL, Carilla-Durand E, Depoortère R, Koek
W, Kleven MS, Colpaert F, Vacher B, Newman-Tancredi A (2010)
F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist:
in-vivo profile in behavioural models of antidepressant and seroto-
nergic activity. Int J Neuropsychopharmacol 13(10):1285–1298
Audero E, Mlinar B, Baccini G, Skachokova ZK, Corradetti R, Gross C
(2013) Suppression of serotonin neuron firing increases aggression
in mice. J Neurosci 33(20):8678–8688
BeekmanM, Flachskamm C, Linthorst AC (2005) Effects of exposure to
a predator on behaviour and serotonergic neurotransmission in dif-
ferent brain regions of C57bl/6Nmice. Eur J Neurosci 21(10):2825–
2836
Brodie BB, Pletcher A, Shore PA (1955) Evidence that serotonin has a
role in brain function. Science 122:968
Psychopharmacology (2016) 233:937–947 945
Cadogan AK, Kendall DA, Fink H, Marsden CA (1994) Social interac-
tion increases 5-HT release and cAMP efflux in the rat ventral hip-
pocampus in vivo. Behav Pharmacol 3:299–305
Calcagnoli F, Stubbendorff C, Meyer N, de Boer SF, Althaus M,
Koolhaas JM (2015) Oxytocin microinjected into the central amyg-
daloid nuclei exerts anti-aggressive effects in male rats.
Neuropharmacology 90:74–81
Caramaschi D, de Boer SF, Vries HD, Koolhaas JM (2008) Development
of violence in mice through repeated victory along with changes in
prefrontal cortex neurochemistry. Behav Brain Res 189:263–272
Carli M, Balducci C,MillanMJ, Bonalumi P, Samanin R (1999) S 15535,
a benzodioxopiperazine acting as presynaptic agonist and postsyn-
aptic 5-HT1A receptor antagonist, prevents the impairment of spa-
tial learning caused by intrahippocampal scopolamine. Br J
Pharmacol 128(6):1207–1214
Carrillo M, Ricci LA, Coppersmith GA, Melloni RH Jr (2009) The effect
of increased serotonergic neurotransmission on aggression: a critical
meta-analytical review of preclinical studies. Psychopharmacol
205(3):349–368
Centenaro LA, Vieira K, Zimmermann N, Miczek KA, Lucion AB, de
Almeida RMM (2008) Social instigation and aggressive behavior in
mice: role of 5-HT1A and 5-HT1B receptors in the prefrontal cortex.
Psychopharmacol 201:237–248
Coccaro EF, Kavoussi RJ, Trestman RL, Gabriel SM, Cooper TB, Siever
LJ (1997) Serotonin function in human subjects: intercorrelations
among central 5-HT indices and aggressiveness. Psychiatry Res
73(1–2):1–14
Coccaro EF, Fanning JR, Phan KL, Lee R (2015) Serotonin and impul-
sive aggression. CNS Spectr 20(3):295–302
Cologer-Clifford A, Simon NG, Lu SF, Smoluk SA (1997) Serotonin
agonist-induced decreases in intermale aggression are dependent
on brain region and receptor subtype. Pharmacol Biochem Behav
58:425–430
Comai S, Tau M, Pavlovic Z, Gobbi G (2012) The psychopharmacology
of aggressive behaviour: a translational approach. J Clin
Psychopharmacol 32:237–260
De Almeida RM, Lucion AB (1997) 8-OH-DPAT in the median raphe,
dorsal periaqueductal gray and corticomedial amygdala nucleus de-
creases, but in the medial septal area it can increase maternal aggres-
sive behavior in rats. Psychopharmacol (Berl) 134:392–400
De Boer SF, Koolhaas JM (2005) 5-HT1A and 5-HT1B receptor agonists
and aggression: a pharmacological challenge of the serotonin defi-
ciency hypothesis. Eur J Pharmacol 526(1–3):125–139
De Boer SF, Lesourd M, Mocaer E, Koolhaas JM (2000) Somatodendritic
5-HT(1A) autoreceptors mediate the anti-aggressive actions of 5-
HT(1A) receptor agonists in rats: an ethopharmacological study with
S-15535, alnespirone, andWAY-100635. Neuropsychopharmacology
23(1):20–33
De Boer SF, van der Vegt BJ, Koolhaas JM (2003) Individual variation in
aggression of feral rodent strains: a standard for the genetics of
aggression and violence? Behav Genetics 33(5):481–497
De Boer SF, Caramaschi D, Natarajan D, Koolhaas JM (2009) The vi-
cious cycle towards violence: focus on the negative feedback mech-
anisms of brain serotonin neurotransmission. Front Behav Neurosci
3:1–6
De Boer SF, Olivier B, Veening J, Koolhaas JM (2015) The neurobiology
of aggression: revealing a modular view. Physiol Behav 146:111–
127
Duke AA, Begue L, Bell R, Eisenlohr-Moul T (2013) Revisiting the
serotonin-aggression relation in humans: a meta-analysis. Psychol
Bull 139(5):1148–1172
Ferris CF, Stolberg T, Kulkarni P, Murugavel M, Blanchard R, Blanchard
DC, Febo M, Brevard M, Simon NG (2008) Imaging the neural
circuitry and chemical control of aggressive motivation. BMC
Neurosci 9:111
Garcia-Garcia A, Newman-Tancredi A, Leonardo ED (2014) 5-HT1A
receptors in mood and anxiety: recent insights into autoreceptor
versus heteroreceptor function. Psychopharmacol (Berl) 231:623–
636
Goedhard LE, Stolker JJ, Heerdink ER, Nijman HLI, Olivier B, Egberts T
(2006) Pharmacotherapy for the treatment of aggressive behaviour
in general adult psychiatry: a systemic review. J Clin Psychiatry
67(7):1013–1024
Haller J, Tóth M, Halász J (2005) The activation of raphe serotonergic
neurons in normal and hypoarousal-driven aggression: a double la-
beling study in rats. Behav Brain Res 161(1):88–94
Haller J, Tóth M, Halasz J, De Boer SF (2006) Patterns of violent
aggression-induced brain c-fos expression in male mice selected
for aggressiveness. Physiol Behav 88(1–2):173–182
Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L,
Depoortère R, Cenci MA, Newman-Tancredi A (2015) NLX-112, a
novel 5-HT1A receptor agonist for the treatment of l-DOPA-induced
dyskinesia: behavioral and neurochemical profile in rat. Exp Neurol
271:335–350
Jacobs BL, Martin-Cora FJ, Fornal CA (2002) Activity of medullary
serotonergic neurons in freely moving animals. Brain Res Brain
Res Rev 40(1–3):45–52
Koolhaas JM, Coppens CM, de Boer SF, Buwalda B, Meerlo P,
Timmermans PJA (2013) The resident-intruder paradigm: a stan-
dardized test for aggression, violence and social stress. J Vis Exp
4:77
Maas JW (1962) Neurochemical differences between two strains of mice.
Science 137(3530):621–622
Mak M, de Koning P, Mos J, Olivier B (1995) Preclinical and clinical
studies on the role of 5-HT1 receptors in aggression. In: Hollander
E, Stein DJ (eds) Impulsivity and aggression. John Wiley & Sons
Ltd, Chichester, England, pp 289–311
Manuck SB, Kaplan JR, Lotrich FE (2006) Brain serotonin and aggres-
sive disposition in humans and nonhuman primates. In: Nelson RJ
(ed) Biology of Aggression. Oxford University Press, New York, pp
65–113
Maurel JL, Autin JM, Funes P (2007) High-efficacy 5-HT1A agonists for
antidepressant treatment: a renewed opportunity. J Med Chem 50:
5024–5033
McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price
LH (1996)A double-blind, placebo-controlled study of fluvoxamine
in adults with autistic disorder. Arch Gen Psychiatry 53(11):1001–
1008
Miczek KA, Faccidomo S, DeAlmeida RM, BannaiM, Fish EW, Debold
JF (2004) Escalated aggressive behavior: new pharmacotherapeutic
approaches and opportunities. Ann N YAcad Sci 1036:336–355
Miczek KA, Takahashi A, Gobrogge KL, Hwa LS, de Almeida RM
(2015) Escalated aggression in animal models: shedding new light
on mesocorticolimbic circuits. Curr Opin Behav Sci 3:90–95
Millan MJ, Canton H, Gobert A et al (1994) Novel benzodioxopiperazines
acting as antagonists at postsynaptic 5-HT1A receptors and as ago-
nists at 5-HT1A autoreceptors: a comparative pharmacological char-
acterization with proposed 5-HT1A antagonists. J Pharmacol Exp
Ther 268(1):337–352
Millan MJ, Newman-Tancredi A, Rivet JM, Brocco M, Lacroix P,
Audinot V, Cistarelli L, Gobert A (1997) S15535, a novel
benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I.
Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3
and h alpha2A-adrenergic receptors in relation to modulation of
cortical monoamine release and activity in models of potential anti-
depressant activity. J Pharmacol Exp Ther 282(1):132–147
Mos J, Olivier B, Poth M, van Aken H (1992) The effects of intraven-
tricular administration of eltoprazine, 1-(3-trifluoromethylphenyl),
piperazine, hydrochloride and 8-OH-DPAT on resident-intruder ag-
gression in the rat. Eur J Pharmacol 212:295–298
946 Psychopharmacology (2016) 233:937–947
Nakazato T (2013) Dual modes of extracellular serotonin changes in the
rat ventral striatum modulate adaptation to a social stress environ-
ment, studied with wireless voltammetry. Exp Brain Res 230(4):
583–596
Newman-Tancredi A (2011) Biased agonism at serotonin 5-HT1A recep-
tors: preferential postsynaptic activity for improved therapy of CNS
disorders. Neuropsychiatry 1(2):149–164
Newman-Tancredi A, Martel JC, Assié MB, Buritova J, Lauressergues E,
Cosi C, Heusler P, Bruins Slot L, Colpaert FC, Vacher B, Cussac D
(2009) Signal transduction and functional selectivity of F15599, a
preferential post-synaptic 5-HT1A receptor agonist. Br J Pharmacol
156(2):338–353
Olivier B (2004) Serotonin and aggression. Ann NYAcad Sci 1036:382–
392
Pelfort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P (2010)
Preferential in vivo action of F15599, a novel 5-HT1A receptor
agonist, at postsynaptic 5-HT1A receptors. Br J Pharmacol 160:
1929–1940
Pfeffer CR, Jiang H, Domeshek LJ (1997) Buspirone treatment of psy-
chiatrically hospitalized prepubertal children with symptoms of anx-
iety and moderately severe aggression. J Child Adolesc
Psychopharmacol 7(3):145–155
Ratey J, Sovner R, Parks A, Rogentine K (1991) Buspirone treatment of
aggression and anxiety in mentally retarded patients: a multiple-
baseline, placebo lead-in study. J Clin Psychiatry 52(4):159–162
Ricketts RW, Goza AB, Ellis CR, Singh YN, Chambers S, Singh NN,
Cooke JC (1994) Clinical effects of buspirone on intractable self-
injury in adults with mental retardation. J Am Acad Child Adolesc
Psychiatry 33(2):270–276
Rosell DR, Siever LJ (2015) The neurobiology of aggression and vio-
lence. CNS Spectr 20(3):254–279
ShaikhMB, De Lanerolle NC, Siegel A (1997) Serotonin 5-HT1A and 5-
HT2/1C receptors in the midbrain periaqueductal gray differentially
modulate defensive rage behavior elicited from themedial hypothal-
amus of the cat. Brain Res 765(2):198–207
Stanislav SW, Fabre T, Crismon ML, Childs A (1994) Buspirone’s effi-
cacy in organic-induced aggression. J Clin Psychopharmacol 14(2):
126–130
Stein DJ, Miczek KA, Lucion AB, de Almeida RM (2013) Aggression-
reducing effects of F15599, a novel selective 5-HT1A receptor ag-
onist, after microinjection into the ventral orbital prefrontal cortex,
but not in infralimbic cortex in male mice. Psychopharmacology
(Berl) 230(3):375–387
Takahashi A, Miczek KA (2014) Neurogenetics of aggressive behavior:
studies in rodents. Curr Top Behav Neurosci 17:3–44
Takahashi A, Quadros IM, de Almeida RM, Miczek KA (2011) Brain
serotonin receptors and transporters: initiation vs. termination of es-
calated aggression. Psychopharmacology (Berl) 213(2–3):183–212
Takahashi A, Quadros IM, de Almeida RM, Miczek KA (2012)
Behavioral and pharmacogenetics of aggressive behavior. Curr
Top Behav Neurosci 12:73–138
Takahashi A, Lee RX, Iwasato T, Itohara S, Arima H, Bettler B, Miczek
KA, Koide T (2015) Glutamate input in the dorsal raphe nucleus as a
determinant of escalated aggression in male mice. J Neurosci
35(16):6452–6463
Underwood BR, Fox C (2014) Citalopram decreases agitation in the
context of Alzheimer’s disease, but at doses higher than those com-
monly prescribed and at the expense of side effects. Evid BasedMed
19(5):181
Valzelli L, Garattini S (1968) Biogenic amines in discrete brain areas after
treatment with monoamineoxidase inhibitors. J Neurochem 15(3):
259–261
Van der Vegt BJ, De Boer SF, Buwalda B, de Ruiter AJ, de Jong JG,
Koolhaas JM (2001) Enhanced sensitivity of postsynaptic serotonin-
1A receptors in rats and mice with high trait aggression. Physiol
Behav 74(1–2):205–211
Van der Vegt BJ, Lieuwes N, Cremers TI, de Boer SF, Koolhaas JM
(2003) Cerebrospinal fluid monoamine and metabolite concentra-
tions and aggression in rats. Horm Behav 44(3):199–208
Vartiainen H, Tiihonen J, Putkonen A, Koponen H, VirkkunenM, Hakola
P, Lehto H (1995) Citalopram, a selective serotonin reuptake inhib-
itor, in the treatment of aggression in schizophrenia. Acta Psychiatr
Scand 91(5):348–351
Veening JG, Coolen LM, de Jong TR, Joosten HW, de Boer SF, Koolhaas
JM, Olivier B (2005) Do similar neural systems subserve aggressive
and sexual behaviour in male rats? Insights from c-Fos and pharma-
cological studies. Eur J Pharmacol 526(1–3):226–239
Walletschek H, Raab A (1982) Spontaneous activity of dorsal raphe neu-
rons during defensive and offensive encounters in the tree-shrew.
Physiol Behav 28(4):697–705
Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, Pollock BG,
Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL,
Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS,
Shade DM, Yesavage J, Lyketsos CG, CitAD Research
Group (2015) Time to response to citalopram treatment for
agitation in Alzheimer disease. Am J Geriatr Psychiatry
S1064–7481
Psychopharmacology (2016) 233:937–947 947
